ValuEngine downgraded shares of Amyris (NASDAQ:AMRS) from a buy rating to a hold rating in a report issued on Monday.
Other equities analysts have also issued reports about the company. HC Wainwright reissued a buy rating and set a $15.00 price target on shares of Amyris in a research note on Monday. Zacks Investment Research downgraded Amyris from a hold rating to a sell rating in a research report on Tuesday, January 30th. Finally, B. Riley assumed coverage on Amyris in a research report on Thursday, January 25th. They set a buy rating and a $8.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $8.19.
Shares of Amyris stock opened at $7.06 on Monday. Amyris has a 12 month low of $1.86 and a 12 month high of $10.65. The company has a debt-to-equity ratio of -0.78, a current ratio of 0.92 and a quick ratio of 0.82.
In other Amyris news, insider John Melo sold 10,776 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total transaction of $50,431.68. Following the sale, the insider now directly owns 83,172 shares in the company, valued at $389,244.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 11.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Compagnie Lombard Odier SCmA raised its position in Amyris by 60.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 39,000 shares during the period. Hudson Bay Capital Management LP purchased a new stake in Amyris during the fourth quarter valued at approximately $451,000. Creative Planning purchased a new stake in shares of Amyris in the fourth quarter worth approximately $188,000. Tanaka Capital Management Inc. raised its holdings in shares of Amyris by 72.0% in the third quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after buying an additional 221,295 shares during the period. Finally, KBC Group NV raised its holdings in shares of Amyris by 228.4% in the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after buying an additional 41,834 shares during the period. Institutional investors and hedge funds own 22.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3335084/amyris-amrs-stock-rating-lowered-by-valuengine.html.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.